RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that a Phase II clinical study evaluating YELIVA™ (ABC294640) in patients with advanced hepatocellular ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE